Boston Scientific Announces Enrollment Of First Patient In Benign Stricture Study Of WallFlex R Biliary RX Stent
Boston Scientific Corporation (NYSE: BSX) announced that the first patient has been enrolled in a clinical trial to evaluate its WallFlex(® ) Biliary RX Fully Covered Stent for the treatment of benign bile duct strictures. This multi-center, prospective study plans to enroll 187 patients at 11 centers(1) worldwide over the next 18 months. The first patient was enrolled by Professor Horst Neuhaus at the Evangelisches Krankenhaus in Dusseldorf, Germany. Lead Investigators in the study are Professor Jacques Deviere of Hospital Erasme in Brussels, and Professor Guido Costamagna of Policlinico A. Gemelli in Rome. "We are pleased to have enrolled the first patient in this important trial to assess the WallFlex Biliary RX Fully Covered Stent as a potential option for the treatment of benign biliary strictures, " said Professor Neuhaus.
Bacteria that produce compounds to reduce inflammation and strengthen host defences could be used to treat inflammatory bowel disease (IBD). Such probiotic microbes could be the most successful treatment for IBD to date, as explained in a review published in the February issue of the Journal of Medical Microbiology. IBD is inflammation of the gastro-intestinal tract that causes severe watery and bloody diarrhoea and abdominal pain. It is an emerging disease that affects 20 out of 100, 000 genetically susceptible people in Europe and North America. The most common manifestations of IBD are Crohn's disease and ulcerative colitis. While the exact causes are unclear, IBD is known to be the result of an overactive immune response that is linked to an imbalance of the normal types of bacteria found in the gut.
Rotavirus is the leading cause of severe, acute gastroenteritis among infants and young children throughout the world and is responsible for an estimated 527, 000 deaths among children under five each year. More than 90% of childhood deaths attributed to rotavirus infection occur in developing countries. Symptoms include severe diarrhoea and vomiting, leading to loss of fluid and electrolytes which can result in dehydration, shock, and death. Safety and efficacy trials have already been conducted with two new rotavirus vaccines in Europe and the Americas which found they were more than 90% effective in preventing severe rotavirus gastroenteritis, but until now, no trials had been carried out in Africa or Asia, where the burden of disease is greatest.
ORLANDO - Everolimus monotherapy shows promising activity and is generally well tolerated in patients with metastatic gastric cancer who have undergone prior anticancer therapy, according to phase 2 results reported by Japanese researchers at the American Society of Clinical Oncology's 2010 Gastrointestinal Cancers Symposium (ASCO GI). Hiroya Takiuchi, MD, with Osaka Medical College, presented results in 53 patients with metastatic gastric cancer who received a daily 10 mg dose oral everolimus. All patients had failed up to two prior chemotherapy regimens. Everolimus is an oral inhibitor of mammalian target of rapamycin (mTOR) that has demonstrated anticancer activity in preclinical cellular and animal models and also in patients with advanced gastric cancer.
New research findings from a team at the Providence Heart + Lung Institute at St. Paul's Hospital and the University of British Columbia (UBC) may lead to new treatment options for abdominal aortic aneurysms (AAA) - a potentially fatal disease that currently has no pharmacological treatments. An aortic aneurysm is a bulging of the aorta, the largest blood vessel in the body. If the aneurysm ruptures, it causes rapid blood loss and a high risk of death. About 75 per cent of all aortic aneurysms occur in the part of the aorta that is located in the abdomen, which supplies blood to the lower limbs. Published in the American Journal of Pathology, a study led by Dr.
Tranzyme Pharma Announces Approval Of Generic Name Ulimorelin For TZP-101, Its First-in-Class Drug Candidate For The Treatment Of GI Dysmotility
Tranzyme Pharma today announced that the United States Adopted Name Council (USAN) has approved the generic name "ulimorelin" for Tranzyme's novel, late-stage, prokinetic agent TZP-101. Ulimorelin, if approved, is expected to be a first-in-class drug for the treatment of gastrointestinal (GI) dysmotility indications in acute care (hospital-based) settings. Ulimorelin is a small molecule, intravenously-administered drug that targets the ghrelin receptor; ghrelin is responsible for energy homeostasis, appetite regulation and gastro-intestinal motility. The safety and pharmacokinetic profiles of ulimorelin have been extensively characterized in healthy subjects and patients across multiple dose levels, and the GI prokinetic properties of the compound have been well established in humans.